Tuhura Biosciences, Inc. (HURA) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Tuhura Biosciences, Inc. on November 4, 2025, reporting events occurring on November 3, 2025. The Company is a Nevada corporation with its principal executive offices in Tampa, Florida, and its common stock trades on the Nasdaq Capital Market under the symbol "HURA".
Key Financial Metrics
The filing does not provide specific financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity for the current or prior periods. The document focuses exclusively on a new financing arrangement.
Material Changes and Agreements
On November 3, 2025, the Company entered into an At The Market Offering Agreement with H.C. Wainwright & Co., LLC. Key terms include:
- Offering Size: The Company may offer and sell shares of common stock with an aggregate offering price of up to $50,000,000.
- Agent and Commission: Wainwright will act as the sales agent and receive a cash commission of 3.0% of the gross sales price of shares sold.
- Legal Fees: The Company agreed to reimburse Wainwright for legal counsel fees up to $75,000.
- Registration: Sales will be made pursuant to a shelf registration statement on Form S-3 filed on November 3, 2025. No shares may be sold until the SEC declares the registration statement effective.
- Use of Proceeds: The Company intends to use all proceeds for working capital and general corporate purposes.
Guidance, Risks, and Contingencies
The Company explicitly states it is not obligated to sell any shares under the agreement. There is no assurance that any shares will be sold, nor any assurance regarding the price, number of shares, or timing of potential sales. Either the Company or Wainwright may suspend offers and sales at any time, and the agreement may be terminated by either party upon proper notice.
Investor Verification Checklist
- Verify the effective date of the Form S-3 Registration Statement (File No. 333-291239) to confirm when sales can commence.
- Review the full text of the Offering Agreement (Exhibit 10.1) for specific covenants and termination rights.
- Monitor future filings for actual sales activity, share counts issued, and proceeds received under the program.
- Assess the impact of potential dilution on existing shareholders if the full $50,000,000 is sold.